Skip to main content

Table 4 Heart failure outcome trials completed in 2020: comparison of active vs. placebo group

From: Report from the CVOT Summit 2020: new cardiovascular and renal outcomes

EMPEROR-reduced [30]

SOLOIST-WHF [31

Class & Cardiovascular outcomes

HR (95.6% CI) p-value

Class & Cardiovascular outcomes

HR (95.6% CI) p-value

Primary composite outcome

Composite of CV death or hospitalisation for HF

0.75 (0.65–0.86)

p < 0.001

Primary composite outcome

Total occurrences of CV death, HHF, and urgent visits for HF

0.67 (0.52–0.85)

p < 0.001

Secondary outcome

Total no. of hospitalisations for HF

0.70 (0.58–0.85)

p < 0.001

Secondary outcome

Total occurrence of HF events

0.64 (0.49–0.83)

p < 0.001

Secondary outcome

Mean slope of change in eGFR — ml/min/1.73 m2 per year

1.73 (1.10–2.37)

p < 0.001

Secondary outcome

CV death

0.84 (0.58–1.22)

p = 0.36

Other prespecified analyses

Composite kidney outcome

0.50 (0.32–0.77)

Secondary outcome

3P-Mace and HHF events

0.72 (0.56–0.92)

Other prespecified analyses

No. of hospitalisation for any cause

0.85 (0.75–0.95)

Secondary outcome

All-cause mortality

0.82 (0.59–1.14)

Other prespecified analyses

All-cause death

0.92 (0.77–1.10)

Adverse events

Event rate (%) active vs. placebo group

Adverse events

Event rate (%) active vs. placebo group

Worsening renal function

3.2 vs. 5.1

Diarrhea

6.1 vs. 3.4

Genital tract infections

1.7 vs. 0.6

Severe hypoglycaemia

1.5 vs. 0.3

Hypotension

9.4 vs. 8.7

Hypotension

6.0 vs. 4.6